real-world experiences with toxicity in patients treated with car-t cell therapy
Published 1 year ago • 163 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
1:31
strategies to minimize the occurrence of crs and icans in patients treated with car-t therapy
-
2:48
the novel icaht grading system to predict toxicity following car t-cell therapy
-
5:07
improving the quality of life of patients treated with car-t therapy
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
1:02
the use of car-t cell products in a real-world setting
-
1:06
efficacy & toxicity of car-t therapy in patients with secondary cns involvement
-
2:31
car t-cell therapy toxicities in b-cell lymphomas
-
0:42
talquetamab treatment in patients with r/r myeloma with prior exposure to t-cell-directed therapies
-
2:06
managing and treating crs, neurological toxicity and cytopenias associated with car-t therapy
-
2:27
the potential of car t-cell therapy in combination with antibodies for the treatment of all
-
2:56
dealing with car t-cell therapy neurotoxicity
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:38
challenges of car-t therapy in the real-world setting
-
14:25
an overview of novel innovative treatments for patients with von willebrand disease
-
1:56
identifying and managing patients at high risk of developing toxicities following car-t therapy
-
2:52
managing toxicity post-car-t therapy in multiple myeloma
-
2:30
the management of car-t related toxicities in leukemia and lymphoma
-
2:05
the cost-effectiveness of car t-cell therapy
-
2:45
car-t treatment outcomes: mm real-world data